Exciting News from Niclosavir Limited!
Born from a pivotal idea during the Covid-19 pandemic, Niclosavir Limited emerged as a beacon of innovation in the fight against antimicrobial resistance (AMR). A novel way to reduce the use of antibiotics in the food chain and the environment.
Our journey began with a simple question: Are there alternative pathways to effectively combat viruses, bacterial infections, and even cancer?
As we delved deeper into our research, one truth became evident: AMR poses a critical threat to global health.
‘…The rise of antimicrobial resistance will be a central challenge of the 21st Century. In fact, the World Health Organization has said antibiotic resistance is one of the greatest global health challenges we face….’
Consider this 👇🏼
- In 2019, bacterial AMR directly contributed to 1.27 million deaths worldwide and was a factor in 4.95 million more (1).
- The misuse and overuse of antimicrobials in humans, animals, and agriculture are the primary culprits driving the rise of drug-resistant pathogens, not to mention the staggering financial costs incurred annually.
At Niclosavir Limited, we are committed to pioneering new solutions that not only combat AMR but also pave the way for healthier futures worldwide.
If you're interested in learning more about how Niclosavir Ltd could safeguard human and animal health, or if you would like to support our efforts to treat this very costly disease, please get in touch at info@niclosavir.com
Visit our website to learn more about our approach: https://lnkd.in/gJV59Cjq
Explore the link below to learn more about this urgent global issue:
https://lnkd.in/f8AXVGX
#AntimicrobialResistance #HealthcareInnovation #GlobalHealth #Biotechnology #NiclosavirLimtied #Mastitis